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Predictors of renal function following lung or heart-lung trans- Increased numbers of long-term survivors of non-renal
plantation. solid organ transplantation have resulted from the greater
Background. Renal failure is a common complication fol- success and availability of these procedures. However,lowing non-renal solid organ transplantation. The purpose of
as the patients survive longer, they are at higher risk forour study was to define the rate of decline in renal function
the medical complications of immunosuppressive ther-and to identify independent risk factors associated with renal
failure following lung or heart-lung transplantation. apy, particularly of calcineurin inhibitors. Among these
Methods. Between May 1986 and December 1998, 219 pa- complications, renal insufficiency is an increasingly com-
tients underwent lung or heart-lung transplantation at the Uni- mon problem [1–4]. Recent reports have shown that 2versity of Minnesota and survived at least six months (33 heart-
to 18% of the patients who receive liver, heart, or lunglung, 66 bilateral single lung, and 120 unilateral single lung
transplants develop severe renal insufficiency and abouttransplants). The mean age at the time of transplant was 45.9
11.6 years (mean  SD; range, 15 to 65 years), and the mean half of these will have end-stage renal disease (ESRD)
pre-transplant serum creatinine level was 0.88  0.19 mg/dL. by ten years post-transplantation [1–9]. The degree of
All patients were treated with a calcineurin inhibitor (164 cyclo- renal functional impairment and the rate of progression
sporine, 55 tacrolimus).
of renal failure depend in part on the organ transplantedResults. During the follow-up period (median 44 months,
and differ significantly among individuals.range 6.8 to 163 months), 16 patients (7.3%) developed end-
stage renal disease. The cumulative incidence of doubling of Studies following lung or heart-lung transplantation
serum creatinine was 34% at one year, 43% at two years and have carefully documented the natural history of the
53% by five years. Factors associated with the primary end point decline in renal function that occurs in these patients [8,
of the time to doubling of the baseline serum creatinine by 10–13]. Most transplant recipients begin to develop someproportional hazards regression were cumulative periods with
renal insufficiency in the first six months post-trans-diastolic blood pressure greater than 90 mm Hg [relative risk
plantation. Between 4 and 7% of these patients go on to(RR) 1.30, P  0.02] and the serum creatinine value at one
month post-transplantation (RR 1.28, P 0.03). Use of tacroli- develop ESRD, with a much larger proportion having
mus during the first six months after transplantation was associ- more moderate decrements in renal function [8, 10–13].
ated with a significant decrease in the risk for time to doubling Identification of those patients at high risk for the devel-of serum creatinine (RR 0.38, P  0.009) and a lower rate of
opment of advanced renal failure or ESRD would allowacute rejection.
appropriate targeting of therapeutic interventions. TheConclusions. These results suggest that potential renopro-
tective strategies following lung or heart-lung transplantation small numbers of patients reported in these individual
include avoidance of peri-transplant renal injury, diligent blood studies (between 19 and 67 patients) have limited their
pressure control, and preferential use of tacrolimus over cyclo- ability to identify risk factors for progression. The pur-sporine.
pose of our study, involving 219 patients following lung
or heart-lung transplantation, was to define the rate of
decline in renal function following transplantation and
more importantly, to identify risk factors associated with
the primary end point of the time to doubling of the
Key words: kidney function, progressive renal disease, graft complica- baseline serum creatinine.
tions, heart-lung transplant, solid organ transplantation, renoprotection.
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Table 1. Baseline characteristics monary artery clamp followed by 250 mg intravenously
every eight hours for three doses. Prednisone was thenType of transplant
Single lung 120 (55%) started at 0.5 mg/kg/day in two divided doses tapering to
Bilateral single lung 66 (30%) 0.1 mg/kg/day at six months post-transplantation. Patients
Heart-lung 33 (15%)
received either CsA [initial target level 200 ng/mL, mea-Pulmonary diagnosis
Cystic fibrosis 17 (8%) sured by high-pressure liquid chromatography (HPLC)
Emphysema 118 (54%) in whole blood throughout the study period] or tacroli-
Pulmonary hypertension and Eisenmenger’s 42 (19%)
mus [initial target level 10 ng/mL measured by micropar-Other 42 (19%)
Gender male:female 91:128 ticle enzyme immunoassay (MEIA) in whole blood].
Drug use Both CsA and tacrolimus target drug levels were reduced
cyclosporine:tacrolimus 164:55
by 10 to 25% after six months, and both were adminis-Mean age (range) 45.911.6 (15–65)
Baseline creatinine mg/dL 0.880.19 tered twice per day. Assignment of drugs was by treating
Baseline creatinine clearancea mL/min 9233 physician preference (164 CsA, 55 tacrolimus). Most pa-
Pre-transplant hypertension 19 (8.6%)
tients on Sandimmune where changed to Neoral withHypertension treated with medication 12 (5.5%)
Pre-transplant diabetes 14 (6.4%) its introduction. Between May 1986 and October 1996
a Estimated using the Cockcroft-Gault equation immunosuppression included azathioprine 2 to 2.5 mg/
kg/day. After October 1996, patients received mycophe-
nolate mofetil (MMF) 2 to 3 g/day. For the purposes of
risk factor analysis recipients were assigned to the cyclo-
and December 1998. We reviewed the course of 219 sporine or tacrolimus group if they remained on a given
patients who survived more than six months following a calcineurin inhibitor throughout the first six months. If
first lung or heart-lung transplant. The point at which they were switched from one calcineurin inhibitor to the
patients experienced a doubling of their creatinine varied other they were considered in the “use of both” group.
over time. A landmark plot of 1/creatinine was used to Follow-up of patients Patients were seen at least every
compare the rate of decline in renal function between other month for the first year after transplantation and
all patients that had doubled their serum creatinine by at least every six months thereafter. The median follow-
24 months (N  82) compared to the rate in patients up duration was 44 months (range 6.8 to 163 months). At
who did not double their serum creatinine by 24 months all clinic visits blood pressure was recorded, medications
(N  132). Five patients did not survive to 24 months. were reviewed, and blood was drawn for renal function
We next analyzed for risk factors for time to doubling of and immunosuppression levels. Surveillance transbron-
serum creatinine. Time to doubling of serum creatinine chial lung biopsies were done at 1, 2, 4, 6, 8, 10, and 12
was chosen as the primary end point as it is a widely ac- months after transplantation unless contraindicated by
cepted surrogate for the development of ESRD [14–17]. coagulopathy or the patient’s clinical status. Biopsies also
Possible risk factors were first screened in bivariate were done when clinically indicated (decrease in pulmo-
analysis to identify candidates for a multivariate analysis. nary function, signs or symptoms of lung dysfunction, ab-
These candidate variables were then entered into a final normal chest radiograph). Transbronchial biopsies were
proportional hazards regression model. graded for acute rejection according to the International
Society of Lung Transplantation criteria [18]. A bronchi-
Patient population olitis obliterans score (BOS) was assigned to each patient
Baseline demographic data of the patients are shown according to the following criteria: 0  FEV1 80% of
in Table 1. The mean age of the patients was 45.9  11.6 baseline; 1  FEV1 67% to 80% of baseline; 2  FEV1
years (mean  SD) with an age range of 15 to 65 years. between 51 and 66% of baseline; 3  FEV1 51% of
Thirty-three patients had heart-lung, 66 bilateral single baseline, where FEV1 is forced expiratory volume in one
lungs, and 120 unilateral single lung transplants. Prior second.
to transplantation, 19 patients had been diagnosed with
Statistical analysishypertension and 12 required therapy. Also, 14 patients
had been diagnosed as having diabetes prior to trans- Data for this study were obtained from the University
plant and all of these patients were hypertensive at base- of Minnesota Lung Transplant Database, an ongoing
line evaluation. database tracking lung and heart-lung transplant recipi-
ents. Additional data elements were obtained from the
Immunosuppression Renal Transplant Database and by means of chart review.
The immunosuppressive regimen consisted of a single Unless stated otherwise, data are expressed as mean 
oral dose of either cyclosporine (CsA; 5 mg/kg) or tacro- standard deviation. Acute rejection rates were compared
limus (0.05 mg/kg) pre-transplant. Methylprednisone 500 between therapy groups using a Kruskal-Wallis analysis
of variance (ANOVA). Time to BOS grade 2 was as-mg was given intravenously following release of the pul-
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sessed using the method of Kaplan-Meier. Possible risk
factors for time to doubling of serum creatinine were
first screened in bivariate analysis to identify candidates
for a multivariate analysis. The association between cate-
gorical variables and time to doubling of creatinine was
assessed using the method of Kaplan-Meier. The categori-
cal variables defined the strata to be compared, which was
accomplished using a log-rank chi-square test. Propor-
tional hazards regression was used to assess interval data,
such as age, and also time-dependent data. To test the
proportional hazards assumption in the models, a time
by covariate interaction effect was introduced into the
model and its significance assessed. The coefficients for
these interaction effects were not significant indicating
that there was no evidence that the effect of the covari-
Fig. 1. Rates of progression of renal disease. Median slope of 1/Crates varied substantially over time. The impact of time-
over the first 24 months post-transplantation for patients who surviveddependent data, such as cumulative periods of diastolic
at least 24 months and had doubled their creatinine by 24 months (;
blood pressure over 90 mm Hg, was assessed at each N  82) versus those who had not doubled by 24 months (; N  132).
The median slope in the first 6 months was significantly different in theevent (doubling of creatinine) time. For example, if a
doublers (0.075) versus non-doublers (0.049; P  0.001 by Mann-doubling of creatinine occurred at one year, for each
Whitney U test). No difference in the median slopes was seen between
subject still in the analysis, a variable would be created 6 and 24 months in doublers versus non-doublers (0.010 vs. 0.008).
that held the count of how many of the possible evalua-
tion time points (0, 1, 3, 6 and 12 months) that patient
had a diastolic blood pressure 90 mm Hg. Risk factors
1.67 0.88 mg/dL at 12 months (N 196), and to 1.98that were associated with time to doubling of creatinine
1.1 mg/dL at three years post-transplant (N  98).at a P  0.1 level were considered candidates for the
Overall, 200 patients (91.3%) had a decrease in renalmultivariate analysis. These variables were then entered
function by six months defined as a negative slope ofinto a final proportional hazards regression model that
the reciprocal of the serum creatinine (1/Cr) versus time.included all candidate variables. Final results were con-
Compared to the pre-transplant serum creatinine, thesidered significant at the 0.05 level.
cumulative incidence of doubling of creatinine was 34%,
For the landmark plot, median slopes were compared
43% and 53% at one, two and five years, respectively.
between the groups defined at 24 months post-transplant Since the point at which patients experienced a doubling
using a Mann-Whitney U test. Since our study and others of their creatinine varied over time, a landmark plot
indicated that most of the loss of renal function occurs in was constructed to compare the rate of decline in renal
the first six months, we compared median slopes between function between patients whose values doubled versus
doublers and non-doublers both in the first 6 months those who did not double their serum creatinine. For
and from 6 to 24 months. In this comparison, for patients subjects who survived at least 24 months, those who
who had survived at least 24 months, the rate of decline had a doubling of serum creatinine by 24 months had a
in renal function for those who had doubled their serum median slope for 1/Cr of 0.075 (0.23 to 0.06) for the
creatinine by 24 months (N  82) were compared to the first six months compared to 0.049 (0.19 to 0.08) for
rate in patients who did not double their serum creatinine the group whose values hadn’t doubled by 24 months
by 24 months (N  132); five patients did not survive to (P  0.001, Mann-Whitney U Test; Fig. 1). The median
24 months. slope was not different between the doublers versus non-
doublers between 6 and 24 months with values of0.010
(range 0.17 to 0.01) versus 0.008 (range 0.008 toRESULTS
0.03, respectively; P  0.1) for both, indicating that the
Renal function difference in loss of renal function between the two
The mean pre-transplant serum creatinine was 0.88  groups occurred in the first six months. There was also
0.19 mg/dL. During the 30-day post-operative period, 37 no association between time to serum creatinine dou-
patients (16.9%) had a doubling of serum creatinine bling and the pre- and post-MMF use eras, suggesting
and 10 (4.6%) required hemodialysis. Of those needing that use of MMF did not affect renal survival.
hemodialysis, two patients (20%) went on to develop Sixteen out of 219 patients (7.3%) developed ESRD
ESRD. For all recipients, mean serum creatinine in- in a median duration of 28 months (mean 32.8  29.0
months; range 3 to 112.5 months). Thirteen out of 16creased to 1.22  0.82 mg/dL at one month (N  219),
Ishani et al: Renal function after lung/heart-lung transplantation 2231
Table 2. Multivariate associations with time to doubling diagnosis, the type of transplant, use of both CsA and
of serum creatinine
tacrolimus during the first six months in the post-trans-
Relative risk plant course, and age at transplantation (Table 2).
Variable (95% CI) P value
Creatinine at 1 month 1.30 (1.02, 1.7) 0.03 Acute and chronic rejection rates
Cumulative periods with DBP 90 mm Hg 1.28 (1.05, 1.6) 0.02
To assess whether the renal protection offered by ta-Tacrolimus vs. CsA 0.38 (0.19, 0.79) 0.009
Any smoking 1.20 (0.66, 2.3) 0.52 crolimus was at the expense of lessened immunosuppres-
PPH or Eisenmenger’s vs. emphysema 0.57 (0.23, 1.4) 0.22 sion, rates of acute and chronic rejection were compared
Other diagnoses vs. emphysema 1.05 (0.60, 1.9) 0.87
between therapy groups. Acute rejection rates, definedBSL vs. SL 0.98 (0.54, 1.77) 0.94
Heart/lung vs. SL 0.98 (0.42, 2.3) 0.96 as episodes of rejection grade  1 per biopsy (bx) per
Both drugs vs. CsA 1.60 (0.82, 3.2) 0.17 month of follow-up, were higher in patients treated with
Age at transplant 1.02 (0.99, 1.05) 0.13
CsA (0.013 0.02/bx/month) compared to those treatedCumulative incidence of acute rejection 1.10 (0.83, 1.5) 0.47
Use of MMF 0.85 (0.45, 1.6) 0.61 with tacrolimus (0.006 0.008/bx/month; P 0.05). Sur-
vival free from BOS grade 2 did not differ between theModel is based on variables significant at the bivariate level. Abbreviations are:
BSL, bilateral single lung; SL, single lung; CI, confidence interval; DBP, diastolic groups. Two-year survival free from BOS grade 2 was
blood pressure; CsA, cyclosporine; PPH, primary pulmonary hypertension; MMF,
81% for the CsA group and 89% for the tacrolimusmycophenolate mofetil.
group (log-rank Chi-square  0.52, d.f.  1, P  .47).
DISCUSSIONpatients had been treated with CsA and three out of 16
with tacrolimus. Seven out of the 16 ESRD patients Nephrotoxicity is a well recognized complication fol-
lowing non-renal solid organ transplantation. It has beenwere treated with hemodialysis only. The remaining nine
patients received kidney transplants; two had a preemp- estimated that 10 years after transplantation 12% of
heart, 2 to 7% of lung and 4% of liver patients developtive transplant and the other seven were dialyzed for a
severe renal insufficiency [4]. Our findings demonstratemedian duration of 14.5 months prior to renal transplanta-
that in a large cohort of 219 patients followed for ation (mean 17.6  11.9 months; range 1 to 33 months).
median duration of 44 months following lung or heart-
Assessment of risk factors lung transplantation, 16 (7.3%) developed end stage re-
nal failure. Of these patients, nine went on to subsequentVariables that were not found to be associated with
time to doubling of serum creatinine at a P  0.1 level renal transplantation. While only a minority of patients
progressed to ESRD, the majority had worsening renalin the bivariate analysis, and therefore not included in
the multivariate analysis, were the need for perioperative function after transplantation; decline in renal function,
defined as a negative slope of 1/Cr was seen in 91.3%hemodialysis, calcineurin inhibitor dose or drug level, any
nephrotoxic drug exposure, pack-years of cigarettes, pre- of our patients by six months. By five years post-trans-
plantation, the cumulative incidence of doubling of creat-transplant hypertension, pre-transplant diabetes, post-
transplant angiotensin-converting enzyme (ACE) inhibitor inine was 53%.
The rate of decreased renal function is consistent withuse, post-transplant calcium channel blocker use, cumu-
lative periods of systolic BP 140 mm Hg, cumulative what others have reported following lung or lung-heart
transplantation in both adult and pediatric patients [8,incidence of acute lung rejection, use of MMF, number
of episodes with toxic calcineurin drug levels (CsA250 10–13]. Our results suggest that two distinct groups of
patients exist: those who will have more severe renalng/mL or tacrolimus  20 ng/mL), or mean CsA dose
per kg of body weight during the first six months. dysfunction manifested as doubling of serum creatinine,
and those in whom there is a smaller decline in renalRisk factors significantly associated with time to dou-
bling of serum creatinine by multivariate analysis were function. The difference in renal function between these
two groups occurs over the first six months post-trans-the serum creatinine value at one month post-trans-
plantation (RR  1.30; P  0.03) and the number of plantation with similar rates of decline in renal function
after this time period.cumulative follow-up periods with the diastolic blood
pressure greater than 90 mm Hg (RR  1.28, P  0.02; A unique feature of our study is that it involves both
the largest group of lung or heart-lung transplantationTable 2). Only one protective factor could be identified;
the use of tacrolimus during the first six months was patients reported to date, and the longest period of fol-
low-up. Thus, we were able to look at specific risk factorsassociated with a decreased risk for the time to doubling
of serum creatinine (RR  0.38; P  0.009). for renal dysfunction in our patient population by multi-
variate analysis. Since the number of patients that devel-Factors that were significant at the bivariate level but
not in the multivariate analysis with time to doubling of oped ESRD was small, we examined predictors for the
end point of time to doubling of serum creatinine. Inserum creatinine were smoking history, the pulmonary
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this multivariate analysis, factors that predicted time to ated with significant, and in most cases, equivalent neph-
rotoxicity following renal and non-renal solid organ trans-doubling of serum creatinine were the serum creatinine
at one month and cumulative periods of diastolic BP plantation [2, 4, 25–30]. However, minimal data exist on
the outcome of renal function after lung or heart-lunggreater than 90 mm Hg. In addition, we demonstrated that
the choice of calcineurin inhibitor therapy in the first six transplantation using tacrolimus [31]. Our results dem-
onstrate that the use of tacrolimus in the first six monthsmonths following transplantation influenced renal out-
come, with tacrolimus being associated with a decreased was associated with a decreased risk for time to doubling
of serum creatinine compared to cyclosporine. The mech-risk for time to doubling of serum creatinine compared
to cyclosporine. anism for the renoprotective effect seen with tacrolimus
may be related to dosing, as relatively higher levels of cy-The importance of the one-month serum creatinine
measurement has been seen by others in less robust closporine (200 ng/mL) were targeted compared to tacro-
limus (10 ng/mL). Tacrolimus also has been shown toanalyses. For example, Broekroelofs et al demonstrated
in a bivariate analysis that GFR at one month was the cause less hypertension, less hyperlipidemia, and a de-
crease in the production of pro-fibrotic cytokines suchonly predictive factor for the decrease in GFR seen at
24 months [10]. Similarly, Pattison et al, in their study of as transforming growth factor-1 (TGF-1) compared to
cyclosporine [32–35]. Despite the higher levels achieved67 patients following heart-lung transplantation, showed
that the serum creatinine at 1 month predicted severity in the CsA group, rejection rates were higher compared
to tacrolimus. Thus, CsA was not only associated withof renal dysfunction defined as serum creatinine greater
than 2.3 mg/dL [8]. The predictive value of the one- greater nephrotoxicity but also appeared to provide less
effective immunosuppression. Selection bias may havemonth serum creatinine is likely related to renal ischemia
associated with the transplantation procedure as well as played a role in the differences seen between the two
drugs since the choice of tacrolimus versus cyclosporinenephrotoxins administered in the peri-transplant period.
In addition, the one-month creatinine may be a marker was individualized and not randomized. Also, the protec-
tive effect of tacrolimus may have been confounded byfor individuals who are more sensitive to the nephrotoxic
effects of calcineurin inhibitors. Currently, these drugs MMF use. As both tacrolimus and MMF are new drugs a
larger percentage of patients on tacrolimus are on con-are dosed according to levels with the assumption that
all individuals require the same level of immunosuppres- comitant MMF therapy compared to CsA. The addition
of MMF would enable lower, and potentially less nephro-sion. This assumption is likely inaccurate and the one
month serum creatinine may be a predictor of individuals toxic dosages of tacrolimus. However, the addition of
MMF to the bivariate model showed that MMF is not awho may benefit from lower drug level goals. However,
it is not clear whether this can be achieved without com- significant predictor of time to doubling of serum creati-
nine. Also, MMF use did not ameliorate the relative bene-promising the outcomes of the transplanted lungs. Pre-
serving renal function early in the course of transplanta- fit of tacrolimus therapy compared to cyclosporine.
Factors not associated with an increased risk for renaltion is essential if subsequent renal failure is to be
avoided. Identification of patients at risk for renal dys- failure in the bivariate analysis included use of MMF, a
pre-transplant diagnosis of hypertension, diabetes, post-function can be made in the early post-transplant period
and would allow for targeting these patients for such transplant use of ACE inhibitors, or mean CsA dose/kg
after six months. There was also no association with base-therapeutic interventions as aggressive BP control or for
a change in the immunosuppressive protocol [19]. line renal function. The lack of an association between
pre-transplant renal function and subsequent renal failureHypertension is common following solid organ trans-
plantation. New onset hypertension has been attributed is consistent with the results of Navis et al, who showed
that pre-transplant GFR was actually associated with ato multiple causes including high dose corticosteroid use,
increased body weight, and use of calcineurin inhibitors less pronounced decrease in GFR [11]. In our study the
underlying pulmonary diagnosis was not a risk factor, in[4, 20–22]. The results of our multivariate analysis high-
light the importance of early and diligent treatment of contrast to the findings of Broekroelofs et al, who dem-
onstrated that renal impairment was greatest in patientshypertension following lung or heart-lung transplanta-
tion particularly for elevations of diastolic BP greater with cystic fibrosis and less in patients with pulmonary
hypertension. In our patients, neither calcineurin inhibitorthan 90 mm Hg. The agent of choice for treatment of
hypertension could not be identified based on our analy- dose or trough levels were independent risk factors for the
development of renal insufficiency. Large cohort studiessis. Although the numbers were small, no increased risk
or benefit could be attributed to calcium channel block- have demonstrated a varying relationship between trough
CsA levels and progression of renal insufficiency rangingers or ACE inhibitors. The lack of a preferential benefit
of calcium channel blockers has been supported by oth- from a weak association [4, 5] to no association [13, 36]
between the two factors. One possible reason for theseers both in prospective trials and a meta-analysis [23, 24].
Both cyclosporine and tacrolimus have been associ- discordant results is that trough drug levels may not cor-
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